Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

Oncology (Switzerland)

Volumn 84, Issue 4, 2013, Pages 191-199

  Bampo, Chiara ^a   Alessi, Alessandra ^a   Fantini, Simona ^a   Bertarelli, Gaia ^a   De Braud, Filippo ^a   Bombardieri, Emilio ^a   Valvo, Francesca ^a   Crippa, Flavio ^a   Di Bartolomeo, Maria ^a   Mariani, Luigi ^a   Milione, Massimo ^a   Biondani, Pamela ^a   Avuzzi, Barbara ^a   Chiruzzi, Chiara ^a   Pietrantonio, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Capecitabine; Complete response; Pathology; PET; Predictive factor; Radiochemotherapy; Rectal cancer

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HUMAN; LOCALLY ADVANCED RECTAL CANCER; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; STANDARD; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 84872261412     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000345601     Document Type: Article

References (40)

1. Gunderson LL, Sargent DJ, Tepper JE: Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002; 54: 386-396.
2. Sauer R, Becker H, Hohenberger W: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
3. Nelson H, Sargent DJ: Refining multimodal therapy for rectal cancer. N Engl J Med 2011; 345: 690-692.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
5. Janjan NA, Khoo VS, Abbruzzese J: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-1038.
6. Glynne-Jones R, Harrison M: Locally advanced rectal cancer: what is the evidence for induction chemoradiation? Oncologist 2007; 12: 1309-1318.
7. Crane CH, Skibber JM, Feig BW: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003; 97: 517-524.
8. Gavioli M, Bagni A, Piccagli I: Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Dis Colon Rectum 2000; 43: 1075-1083.
9. Suppiah A, Hunter IA, Cowley J: Magnetic resonance imaging accuracy in assessing tumor down-staging following chemoradiation in rectal cancer. Colorectal Dis 2009; 11: 249-253.
10. Bipat S, Glas AS, Slors FJ: Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiology 2004; 232: 773-783.
11. Ciccocioppo A, Stephens JH, Hewett PJ: Complete pathologic response after preoperative rectal cancer chemoradiotherapy. ANZ J Surg 2009; 79: 481-484.
12. Rodel C, Martus P, Papadoupolos T: Prognostic significance of tumor regression after preoperative chemoradiation for rectal cancer. J Clin Oncol 2006; 23: 8688-8696.
13. Capirci C, Valentini V, Cionini L: Prognostic value of pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
14. Habr-Gama A, Perez RO, Nadalin W: Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-718.
15. Glynne-Jones R, Wallace M, Livingstone JI: Complete clinical response after preoperative chemoradiation in rectal cancer: is a 'wait and see' policy justified? Dis Colon Rectum 2008; 51: 10-20.
16. O'Neill BD, Brown G, Heald RJ: Nonoperative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007; 8: 625-633.
17. Maas M, Beets-Tan RG, Lambregts DM: Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29: 4633-4640.
18. Chavaudra J: Last ICRU recommendations for the prescription, recording and reporting of external bean therapy. Cancer Radiother 1998; 2: 607-614.
19. Kim JS, Kim JS, Cho MJ: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408.
20. Mandard AM, Dalibard F, Mandard JC: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
21. Kinahan PE, Fletcher JW: Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31: 496-505.
22. Young H, Baum R, Cremerius U: Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations-European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
23. Roh MS, Colangelo LH, O'Connell MJ: Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-5130.
24. Valentini V, Coco C, Picciocchi A: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002; 53: 664-674.
25. Bouzourene H, Bosman FT, Seelentag W: Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 1121-1130.
26. Hiotis SP, Weber SM, Cohen AM: Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194: 131-135.
27. Guillem J, Chessin D, Shia J: Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol 2005; 23: 3475-3479.
28. Kahn H, Alexander A, Rakinic J: Preoperative staging of irradiated rectal cancers using digital rectal examination, computed tomography, endorectal ultrasound, and magnetic resonance imaging does not accurately predict T0, N0 pathology. Dis Colon Rectum 1997; 40: 140-144.
29. de Geus-Oei LF, Vriens D, van Laarhoven HW: Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009; 50(suppl 1):43S-54S.
30. Capirci C, Rubello D, Chierichetti F: Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother 2004; 58: 451-457.
31. Capirci C, Rubello D, Chierichetti F: Longterm prognostic value of 18-F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol 2006; 187: 202-208.
32. Capirci C, Rubello D, Pasini F: The role of dual-time combined 18-fluorideoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiation Biol Phys 2009; 74: 1461-1469.
33. Martoni AA, Di Fabio F, Pinto C: Prospective study on the FDG-PET/TC predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol 2011; 22: 650-656.
34. Yeung JMC, Kalff V, Hicks RJ: Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome. Dis Colon Rectum 2011; 54: 518-525.
35. Kalff V, Duong C, Drummond EG: Findings on 18 F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006; 47: 14-22.
36. Janssen MHM, Öllers MC, van Stiphout RGPM: PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiation Biol Phys 2012; 82: 871-876.
37. Rosenberg R, Herrmann K, Gertler R: The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009; 24: 191-200.
38. Zhang C, Tong J, Sun X: 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer 2012; 131: 2604-2611.
39. Sawada N, Ishikawa T, Sekiguchi F: X-ray irradiation induces thymidine phosphorilase and enhance the efficacy of capecitabine in human cancer xenograft. Clin Cancer Res 1999; 5: 2948-2953.
40. Hofheinz R, Wenz F, Post S: Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): longterm results of a randomized, phase III trial (abstract 3504). 2011 ASCO Annu Meet, Chicago, 2011.